The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis
Background This meta-analysis aims to assess the efficacy and safety of roxadustat in treating anemia patients with dialysis-dependent (DD) chronic kidney disease (CKD).Methods We comprehensively searched 5 databases for randomized controlled trials (RCTs) investigating roxadustat for anemia in DD-C...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2023.2195011 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850143056640081920 |
|---|---|
| author | Qiaoqiao Zhou Mian Mao Jing Li Furong Deng |
| author_facet | Qiaoqiao Zhou Mian Mao Jing Li Furong Deng |
| author_sort | Qiaoqiao Zhou |
| collection | DOAJ |
| description | Background This meta-analysis aims to assess the efficacy and safety of roxadustat in treating anemia patients with dialysis-dependent (DD) chronic kidney disease (CKD).Methods We comprehensively searched 5 databases for randomized controlled trials (RCTs) investigating roxadustat for anemia in DD-CKD patients. RevMan 5.0 was used to extract and synthesize data for meta-analysis.Results Ten different RCTs (9 studies) and 5698 DD-CKD patients with anemia were included. Our findings revealed that when compared to the erythropoiesis-stimulating agents (ESAs) group, the roxadustat group showed increased hemoglobin levels [MD (Mean Difference) 0.25 g/dL (95%CI 0.14 g/dL to 0.36 g/dL), p < 0.00001] and improved iron-utilization by increasing serum iron [MD 1.85 µmol/L], total iron binding capacity [MD 35.73 µg/dL], transferrin saturation [MD 1.19%], and transferrin level [MD 0.40 g/L]. In addition, we found that roxadustat significantly decreased the low-density lipoprotein-cholesterol [MD −0.39 mmol/L] and total cholesterol [MD −0.6 mmol/L]. In patients with a C-reactive protein level that exceeds the upper limit of the normal range, hemoglobin levels were higher for roxadustat than for ESAs [MD 0.39 g/dL]. Treatment-emergent adverse events, treatment-emergent serious adverse events, and major adverse cardiovascular events were not significantly different between the two groups.Conclusions The hemoglobin levels of DD-CKD patients were significantly increased and not affected by the inflammatory state after roxadustat treatment. Roxadustat also improved iron utilization, and it was not associated with higher treatment-emergent adverse events, treatment-emergent serious adverse events, and major adverse cardiovascular events when compared to ESAs. |
| format | Article |
| id | doaj-art-e1c5b6a62b2042de9fd33e4d42a98e2a |
| institution | OA Journals |
| issn | 0886-022X 1525-6049 |
| language | English |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Renal Failure |
| spelling | doaj-art-e1c5b6a62b2042de9fd33e4d42a98e2a2025-08-20T02:28:50ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492023-12-0145110.1080/0886022X.2023.2195011The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysisQiaoqiao Zhou0Mian Mao1Jing Li2Furong Deng3Hemodialysis Room, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, P.R. ChinaDepartment of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, P.R. ChinaHemodialysis Room, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, P.R. ChinaHemodialysis Room, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, P.R. ChinaBackground This meta-analysis aims to assess the efficacy and safety of roxadustat in treating anemia patients with dialysis-dependent (DD) chronic kidney disease (CKD).Methods We comprehensively searched 5 databases for randomized controlled trials (RCTs) investigating roxadustat for anemia in DD-CKD patients. RevMan 5.0 was used to extract and synthesize data for meta-analysis.Results Ten different RCTs (9 studies) and 5698 DD-CKD patients with anemia were included. Our findings revealed that when compared to the erythropoiesis-stimulating agents (ESAs) group, the roxadustat group showed increased hemoglobin levels [MD (Mean Difference) 0.25 g/dL (95%CI 0.14 g/dL to 0.36 g/dL), p < 0.00001] and improved iron-utilization by increasing serum iron [MD 1.85 µmol/L], total iron binding capacity [MD 35.73 µg/dL], transferrin saturation [MD 1.19%], and transferrin level [MD 0.40 g/L]. In addition, we found that roxadustat significantly decreased the low-density lipoprotein-cholesterol [MD −0.39 mmol/L] and total cholesterol [MD −0.6 mmol/L]. In patients with a C-reactive protein level that exceeds the upper limit of the normal range, hemoglobin levels were higher for roxadustat than for ESAs [MD 0.39 g/dL]. Treatment-emergent adverse events, treatment-emergent serious adverse events, and major adverse cardiovascular events were not significantly different between the two groups.Conclusions The hemoglobin levels of DD-CKD patients were significantly increased and not affected by the inflammatory state after roxadustat treatment. Roxadustat also improved iron utilization, and it was not associated with higher treatment-emergent adverse events, treatment-emergent serious adverse events, and major adverse cardiovascular events when compared to ESAs.https://www.tandfonline.com/doi/10.1080/0886022X.2023.2195011Roxadustatanemiadialysismeta-analysischronic kidney disease |
| spellingShingle | Qiaoqiao Zhou Mian Mao Jing Li Furong Deng The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis Renal Failure Roxadustat anemia dialysis meta-analysis chronic kidney disease |
| title | The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis |
| title_full | The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis |
| title_fullStr | The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis |
| title_full_unstemmed | The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis |
| title_short | The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis |
| title_sort | efficacy and safety of roxadustat for anemia in patients with dialysis dependent chronic kidney disease a systematic review and meta analysis |
| topic | Roxadustat anemia dialysis meta-analysis chronic kidney disease |
| url | https://www.tandfonline.com/doi/10.1080/0886022X.2023.2195011 |
| work_keys_str_mv | AT qiaoqiaozhou theefficacyandsafetyofroxadustatforanemiainpatientswithdialysisdependentchronickidneydiseaseasystematicreviewandmetaanalysis AT mianmao theefficacyandsafetyofroxadustatforanemiainpatientswithdialysisdependentchronickidneydiseaseasystematicreviewandmetaanalysis AT jingli theefficacyandsafetyofroxadustatforanemiainpatientswithdialysisdependentchronickidneydiseaseasystematicreviewandmetaanalysis AT furongdeng theefficacyandsafetyofroxadustatforanemiainpatientswithdialysisdependentchronickidneydiseaseasystematicreviewandmetaanalysis AT qiaoqiaozhou efficacyandsafetyofroxadustatforanemiainpatientswithdialysisdependentchronickidneydiseaseasystematicreviewandmetaanalysis AT mianmao efficacyandsafetyofroxadustatforanemiainpatientswithdialysisdependentchronickidneydiseaseasystematicreviewandmetaanalysis AT jingli efficacyandsafetyofroxadustatforanemiainpatientswithdialysisdependentchronickidneydiseaseasystematicreviewandmetaanalysis AT furongdeng efficacyandsafetyofroxadustatforanemiainpatientswithdialysisdependentchronickidneydiseaseasystematicreviewandmetaanalysis |